leadf
logo-loader
viewAllergy Therapeutics PLC

Allergy Therapeutics says double-digit revenue growth is sustainable

Allergy Therapeutics' (LON:AGY) chief executive officer Manuel Llobet talks to Proactive Investors UK about the company's "very strong" performance in the second half of 2015 as the group's products sales gain momentum in Europe.

Llobet points out the company gained market share across all its markets and for all the products in its portfolio and that the double-digit revenue growth seen over the period is sustainable throughout 2016.

Quick facts: Allergy Therapeutics PLC

Price: 13.375 GBX

AIM:AGY
Market: AIM
Market Cap: £85.58 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Allergy Therapeutics shares tipped to rise to 32p

Allergy Therapeutics plc (LON:AGY) has a chance of rising to around 32p per share, so says technical analyst Zak Mir. In a Tip TV segment for Proactive Investors, Mir highlights the big turnaround in the chart for Allergy Therapeutics and notes that it is now in a rising trend.

on 02/21/2017

2 min read